Advanced search
Publication Cover
Personalized Medicine Volume 10, 2013 - Issue 4
Submit an article Journal homepage
68
Views
0
CrossRef citations to date
0
Altmetric
News & Views

Company Profile: Center for Business Models in Healthcare

Julia R Trosman1 Center for Business Models in Healthcare, 2705 West Agatite Avenue, Suite 200, Chicago, IL60625, USA;2 Feinberg School of Medicine, Northwestern University, Evanston, IL, USA;3 Department of Clinical Pharmacy, University of California, San Francisco, CA, USACorrespondence[email protected]
&
Christine B Weldon1 Center for Business Models in Healthcare, 2705 West Agatite Avenue, Suite 200, Chicago, IL60625, USA;2 Feinberg School of Medicine, Northwestern University, Evanston, IL, USA
Pages 333-337 | Published online: 06 Jun 2013

References

  • Trosman JR , Van Bebber SL, Phillips KA. Health technology assessment and private payers‘ coverage of personalized medicine. J. Oncol. Pract.7(Suppl. 3) , S18–S24 (2011).
  • Trosman JR , Van Bebber SL, Phillips KA. Coverage policy development for personalized medicine: private payer perspectives on developing policy for the 21-gene assay. J. Oncol. Pract.6(5) , 238–242 (2010).
  • Van Bebber SL , TrosmanJR, LiangSY et al. Capacity building for assessing new technologies: approaches to examining personalized medicine in practice. Per. Med. 7(4) , 427–439 (2010).
  • Weldon CB , TrosmanJ, SchinkJC. Cost of cancer: there is more to it than containing chemotherapy costs. Oncology (Williston Park)26(11) , 1116–1118 (2012).
  • Weldon CB , TrosmanJR, GradisharWJ, BensonAB 3rd, Schink JC. Barriers to the use of personalized medicine in breast cancer. J. Oncol. Pract.8(4) , e24–e31 (2012).
  • Trosman JR , WeldonCB, SchinkJC et al. What do providers, payers and patients need from comparative effectiveness research on diagnostics? The case of HER2/Neu testing in breast cancer. J. Comp. Effect. Res. (2013) (In Press).
  • Trosman JR , WeldonCB, GradisharWJ, SchinkJC. Timing of genetic testing relative to breast cancer surgery. J. Clin. Oncol.28(Suppl. 15), Abstract 666 (2010).
  • Van Bebber SL , TrosmanJR, PhillipsKA. One size does not fit all: payers use of evidence frameworks to make coverage and policy decisions. Presented at: AcademyHealth 2010 Annual Research Meeting. Boston, MA, USA, 27–29 June 2010.
  • Schink JC , WeldonCB, TrosmanJR, BensonAB 3rd, Gradishar WJ. Features of an ‘Oncology Medical Home‘: addressing challenges in cancer care delivery. Presented at: AcademyHealth 2010 Annual Research Meeting. Boston, MA, USA, 27–29 June 2010.
  • Trosman JR , WeldonCB, TsongalisGT, PhillipsKA. A standardized BCR-ABL monitoring test: assessment of potential adoption impacts in healthcare in the United States. Blood116 , 4754 (2010).
  • Schink JC , DollKM, WeldonCB et al. Prophylactic oophorectomy for patients with breast cancer with BRCA results. J. Clin. Oncol. 29(Suppl.), Abstract 1533 (2011).
  • Doll KM , WeldonCB, TrosmanJR et al. BRCA+ test result impact and timing on surgical treatment decisions for patients with breast cancer. J. Clin. Oncol. 29(Suppl.), Abstract 626 (2011).
  • Tsongalis GT , WeldonCB, TrosmanJR, GradisharWJ, SchinkJC. Barriers to implementing primary HER2 FISH testing. J. Clin. Oncol.29(Suppl.), Abstract e16642 (2011).
  • Weldon CB , TrosmanJR, DupuyD et al. Are breast cancer screening patients with family cancer history directed to genetic counseling/testing? Cancer Epidemiol. Biomarkers Prev. 20(Suppl. 10) , A38 (2011).
  • Trosman JR , WeldonCB, DupuyD et al. Why do breast cancer programs fail to refer patients to genetic counseling upon obtaining family history? J. Clin. Oncol. 30(Suppl.), Abstract 1553 (2012).
  • Schink JC , WeldonCB, TrosmanJR et al. Biomarker testing methods in breast, gastric and lung cancers – a benchmarking survey of NCI cancer centers. J. Clin. Oncol. 31(Suppl.), Abstract e22093 (2013).
  • Siziopikou KP , WeldonCB, TrosmanJR, GradisharWJ, SchinkJC. What are NCI designated cancer centers using for breast cancer HER2 testing? J. Clin. Oncol.31(Suppl.), Abstract 626 (2013).
  • Trosman JR , WeldonCB, TsongalisGT, SchinkJC, BensonAB 3rd. What are NCI designated cancer centers using for gastric and esophageal cancer HER2 testing? J. Clin. Oncol.31(Suppl.), Abstract e15010 (2013).
  • Weldon CB , TrosmanJR, BensonAB 3rd et al. Are oncologists involved in cancer biomarker decisions at their institutions? J. Clin. Oncol.31(Suppl.), Abstract 6617 (2013).
  • Trosman JR , WeldonCB. Models of care delivery. In: Current Multidisciplinary Oncology: Colorectal Cancer. Benson AB 3rd, Chakravarthy A, Hamilton SR, Sigurdson E (Eds). Demos Medical Publishing, NY, USA (In Press).

▪ Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.